Investigational topical anticholinergics in clinical development for the treatment of hyperhidrosis

Focal hyperhidrosis has an incidence of up to 4.8%. % [1]. Abnormal sympathetic hyperactivity is the best documented component of its pathogenesis.Management of focal hyperhidrosis includes aluminu...

[1]  R. Szeimies,et al.  A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial , 2021, The British journal of dermatology.

[2]  D. Mould,et al.  Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis , 2021, Clinical Pharmacokinetics.

[3]  A. Kume,et al.  A phase 3, multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study of 5% sofpironium bromide (BBI‐4000) gel in Japanese patients with primary axillary hyperhidrosis , 2021, The Journal of dermatology.

[4]  A. Offidani,et al.  Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study , 2020, Dermatologic therapy.

[5]  Ping-Yu Liu,et al.  Efficacy and Safety of Topical Sofpironium Bromide Gel for the Treatment of Axillary Hyperhidrosis: A Phase II, Randomized, Controlled, Double-Blinded Trial. , 2020, Journal of the American Academy of Dermatology.

[6]  D. Rigopoulos,et al.  Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions , 2019, Clinical, cosmetic and investigational dermatology.

[7]  C. Abels,et al.  Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double‐blind, placebo‐controlled study , 2019, The British journal of dermatology.

[8]  J. Gralla,et al.  Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults , 2018, Pediatric dermatology.

[9]  R. Bissonnette,et al.  A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  E. Sprecher,et al.  Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study. , 2017, Acta dermato-venereologica.

[11]  R. M. Rubison,et al.  Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects With Primary Focal Hyperhidrosis. , 2017, Journal of drugs in dermatology : JDD.

[12]  M. Troya-Martín,et al.  Initial study of transdermal oxybutynin for treating hyperhidrosis , 2017, The Journal of dermatology.

[13]  L. Sáez-Martín,et al.  Preliminary Experience with Transdermal Oxybutynin Patches for Hyperhidrosis. , 2016, Actas dermo-sifiliograficas.

[14]  D. Baker,et al.  Topical glycopyrrolate reduces axillary hyperhidrosis , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  I. Son,et al.  Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double‐blinded, placebo‐controlled, split‐face study , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[16]  G. Kavanagh,et al.  Aspergillus fumigatus infection on a home‐made tattoo , 2014, The British journal of dermatology.

[17]  J. Shaw,et al.  A randomised controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating , 1997, Diabetologia.

[18]  E. Zur.  Topical Treatment of Primary Focal Hyperhidrosis, Part 2. , 2019, International journal of pharmaceutical compounding.